In this program, the principal investigator and his collaborators are developing new approaches to the therapy of acute myeloblastic leukemia (AML). The program encompasses clinical, translational and basic science projects. The administrative core will assist the principal investigator in coordinating the activities of the participating members from the Clinical Departments (Leukemia and BMT), the Basci Science Departments (Experimental Therapeutics and Molecular Therapeutics), the Division of Laboratory Medicine, the Biostatistics Department, and the investigators at other institutions (The Burnham Institute, La Jolla, CA;The Salk Institute, La Jolla, CA; The University of Texas Health Science Center, Houston, TX; The Universityof Ohio State Medical School, Columbus, Ohio; The University of Nevada, Reno Nevada) to fulfill the workscope of the program. The Core will identify samples for laboratory studies and provide investigators with ad hoc clinical and laboratory information that is critical for their studies. The Core will also help investigators to organize and control the quality of their data for entry into the Database (Core Cl) for subsequent analysis by Biostatistics (Core C2).The Core will also coordinate the regular meetings of this group, special lectures and the interactions with internal and external advisory committees and will support the tracking of all grant budgets, will assure the integration of all the projects and cores and aid in the publication of reports and manuscripts.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA055164-16
Application #
7726852
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2008-09-01
Budget End
2009-08-31
Support Year
16
Fiscal Year
2008
Total Cost
$161,655
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Ruvolo, Peter P; Ruvolo, Vivian R; Burks, Jared K et al. (2018) Role of MSC-derived galectin 3 in the AML microenvironment. Biochim Biophys Acta Mol Cell Res 1865:959-969
Ngankeu, Apollinaire; Ranganathan, Parvathi; Havelange, Violaine et al. (2018) Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia. Oncotarget 9:4354-4365
Le, Phuong M; Andreeff, Michael; Battula, Venkata Lokesh (2018) Osteogenic niche in the regulation of normal hematopoiesis and leukemogenesis. Haematologica :
Jiang, Xuejie; Mak, Po Yee; Mu, Hong et al. (2018) Disruption of Wnt/?-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in FLT3-Mutant Acute Myeloid Leukemia. Clin Cancer Res 24:2417-2429
Ishizawa, Jo; Nakamaru, Kenji; Seki, Takahiko et al. (2018) Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition. Cancer Res 78:2721-2731
Sekihara, Kazumasa; Saitoh, Kaori; Han, Lina et al. (2017) Targeting mantle cell lymphoma metabolism and survival through simultaneous blockade of mTOR and nuclear transporter exportin-1. Oncotarget 8:34552-34564
Carter, Bing Z; Mak, Po Yee; Wang, Xiangmeng et al. (2017) Focal Adhesion Kinase as a Potential Target in AML and MDS. Mol Cancer Ther 16:1133-1144
Zeng, Zhihong; Liu, Wenbin; Tsao, Twee et al. (2017) High-throughput profiling of signaling networks identifies mechanism-based combination therapy to eliminate microenvironmental resistance in acute myeloid leukemia. Haematologica 102:1537-1548
Pan, Rongqing; Ruvolo, Vivian; Mu, Hong et al. (2017) Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: Mechanisms and Superior Antileukemic Efficacy. Cancer Cell 32:748-760.e6
Jacamo, Rodrigo; Davis, R Eric; Ling, Xiaoyang et al. (2017) Tumor Trp53 status and genotype affect the bone marrow microenvironment in acute myeloid leukemia. Oncotarget 8:83354-83369

Showing the most recent 10 out of 422 publications